This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, ...

This issue highlights a broader concern regarding medication coverage and affordable health care. It underscores the critical ...

GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results.

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued ...

The change means that Maine members of Harvard Pilgrim Health Care will have access to all eight HIV medications and they'll be covered either through CoverMe.gov or a small emplo ...

Harvard Pilgrim Health Care reversed a decision to stop covering certain HIV medications to Mainers, news of which created anxiety and confusion during the state's open enrollment period. The reversal ...

The Maine Bureau of Insurance announced Monday that the carrier reversed its initial decision and will cover eight HIV ...

A new report from the Institute for Clinical and Economic Review showed that recent unsupported price hikes for top-selling drugs contributed to $815 million to U.S. medical spending in 2023. Here are ...